US equities |
NVDA $177.69 ▼-4.80% AMD $501.31 ▲+11.64% MU $734.50 ▲+6.45% SPCX $142.06 ▲+5.80% SNDK $901.90 ▲+8.00% AMZN $268.69 ▲+3.62% TSLA $378.00 ▲+5.52% META $643.07 ▲+5.40%
FinancialContent

DBV Technologies S.A. - American Depositary Shares (NQ:DBVT)

11.29 +0.84 (+7.99%)
Delayed Quote Updated: 12:10 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DBV Technologies S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears ↗
DBV Technologies (NASDAQ:DBVT) is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on whether regulators will accept its biologics... 
Via MarketBeat
News headline image
DBV Technologies to Participate in Upcoming November Investor Conferences
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies (DBVT) Q3 2026 Earnings Call Transcript ↗
Net loss widened to $64.5 million as company scales commercial operations. 
Via The Motley Fool
Topics Earnings
News headline image
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call ↗
DBV Technologies (NASDAQ:DBVT) said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing... 
Via MarketBeat
Topics Earnings
News headline image
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in Upcoming September Investor Conferences
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Q2 Earnings Call Highlights ↗
DBV Technologies (NASDAQ:DBVT) said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7,... 
Via MarketBeat
Topics Earnings
News headline image
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces the Results of its 2026 Combined General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Combined General Meeting of June 3, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports First Quarter 2026 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >